Acuta Capital Partners Reduces Ocular Therapeutix Holdings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: NASDAQ.COM
- Share Reduction Details: Acuta Capital Partners reduced its holdings in Ocular Therapeutix by 460,887 shares in Q1, bringing its total to 592,108 shares valued at approximately $5 million, which now represents 3.5% of the firm's AUM.
- Market Performance Lag: Ocular Therapeutix shares gained only 12.7% over the past year, significantly trailing the S&P 500's 30.4% and the Nasdaq Composite's 41.5%, indicating investor concerns about its growth potential.
- Poor Financial Performance: The company reported only $10.8 million in revenue for Q1 while incurring a loss of $88.6 million, highlighting its vulnerability in a competitive market and necessitating cautious risk assessment by investors.
- Uncertain Future Outlook: Although Ocular Therapeutix is conducting trials for several products that could lead to significant revenue increases if successful, the uncertainty surrounding government approvals poses challenges for investment, prompting investors to watch for updates from the investor day on June 17.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OCUL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OCUL
Wall Street analysts forecast OCUL stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.150
Low
20.00
Averages
23.43
High
31.00
Current: 9.150
Low
20.00
Averages
23.43
High
31.00
About OCUL
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Acuta Capital Reduces Stake in Ocular Therapeutix Significantly
- Share Reduction Details: According to an SEC filing dated May 15, Acuta Capital Partners sold 460,887 shares of Ocular Therapeutix in Q1, leaving them with 592,108 shares valued at approximately $5 million, indicating a cautious outlook on the company's future prospects.
- Asset Management Proportion: Following this sale, Ocular Therapeutix now represents only 3.5% of Acuta Capital's AUM, down from 8.7% at the end of last year, reflecting investor concerns regarding its performance.
- Company Financial Performance: As of market close on May 26, Ocular Therapeutix's stock was priced at $8.29, with a 12.7% increase over the past year, yet this lags behind the S&P 500's 30.4% and Nasdaq Composite's 41.5%, indicating poor market performance.
- Future Outlook and Risks: Despite Ocular Therapeutix conducting trials for several products, the company reported only $10.8 million in revenue for Q1 and a loss of $88.6 million, prompting investors to watch for updates during the investor day on June 17 for insights into its future developments.
See More
Acuta Capital Partners Reduces Ocular Therapeutix Holdings
- Share Reduction Details: Acuta Capital Partners reduced its holdings in Ocular Therapeutix by 460,887 shares in Q1, bringing its total to 592,108 shares valued at approximately $5 million, which now represents 3.5% of the firm's AUM.
- Market Performance Lag: Ocular Therapeutix shares gained only 12.7% over the past year, significantly trailing the S&P 500's 30.4% and the Nasdaq Composite's 41.5%, indicating investor concerns about its growth potential.
- Poor Financial Performance: The company reported only $10.8 million in revenue for Q1 while incurring a loss of $88.6 million, highlighting its vulnerability in a competitive market and necessitating cautious risk assessment by investors.
- Uncertain Future Outlook: Although Ocular Therapeutix is conducting trials for several products that could lead to significant revenue increases if successful, the uncertainty surrounding government approvals poses challenges for investment, prompting investors to watch for updates from the investor day on June 17.
See More
Saturn V Capital Management Fully Exits Ocular Therapeutix
- Full Exit from Holdings: On May 15, 2026, Saturn V Capital Management disclosed a complete exit from its 1,504,880 shares in Ocular Therapeutix, with an estimated transaction value of $14.34 million, indicating a decline in confidence in the company.
- Valuation Shift: Following the sale, Saturn V's position in Ocular fell to zero, with a quarter-end valuation shift of $18.27 million, highlighting the impact of market price fluctuations on its investment portfolio.
- Poor Financial Performance: Ocular Therapeutix reported a less than 1% revenue increase to $10.8 million in Q1, while R&D expenses surged to $66.2 million, resulting in a widened net loss of $88.6 million, reflecting significant financial pressure on the company.
- Future Outlook and Challenges: Despite positive clinical trial results, the market remains cautious about Ocular's ability to convert clinical data into commercial success, especially with a cash balance of $666.7 million, making future execution critical for its growth prospects.
See More
Saturn V Fully Exits Ocular Therapeutix Stake
- Share Sale Details: Saturn V Capital Management sold 1,504,880 shares of Ocular Therapeutix in Q1 2026, with an estimated transaction value of $14.34 million, marking a complete exit from the company, which previously represented 3.4% of the fund's AUM.
- Asset Value Decline: The fund's quarter-end position value decreased by $18.27 million due to both share sales and market price fluctuations, indicating a total divestment from Ocular and reflecting diminished confidence in the company's future prospects.
- Financial Performance Analysis: Ocular Therapeutix reported a less than 1% revenue increase to $10.8 million in Q1, while R&D expenses surged to $66.2 million, leading to a net loss of $88.6 million, highlighting financial strain amid commercialization efforts.
- Market Outlook: Despite short-term challenges, Ocular retains a cash balance of $666.7 million, projected to last until 2028, with the market eager for proof that the company can convert promising clinical data into commercial success, although analysts remain cautious about its future performance.
See More
Ocular Therapeutix Q1 2026 Earnings Call Insights
- Clinical Trial Breakthrough: Ocular Therapeutix's SOL-1 Phase III trial results indicate that AXPAXLI is the first investigational therapy to surpass an approved anti-VEGF agent in treating wet AMD, with 2/3 of patients maintaining vision for an entire year after just one injection, marking a significant advancement in the treatment landscape.
- Regulatory Pathway Planning: The company intends to submit a New Drug Application (NDA) based on SOL-1 Week 52 data and plans to leverage the 505(b)(2) pathway to shorten review timelines, a strategy that will accelerate the commercialization process for AXPAXLI.
- Strong Financial Position: As of Q1 2026, the company reported approximately $667 million in cash, expected to sustain operations into 2028, although management cautioned that this does not cover all expenses anticipated for AXPAXLI's commercialization.
- Future Outlook: Management anticipates releasing SOL-R top-line data in Q1 2027 and plans to provide detailed updates on the NDA submission strategy and commercialization plans during the Investor Day on June 17, reflecting the company's confidence in future growth.
See More
Ocular Therapeutix to Announce Q1 Earnings on May 5th
- Earnings Announcement Date: Ocular Therapeutix (OCUL) is set to announce its Q1 earnings on May 5th before market open, with a consensus EPS estimate of -$0.32, reflecting a 15.8% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Expectations: The anticipated revenue for Q1 is $12.7 million, representing an 18.7% year-over-year increase, which highlights a positive trend in market demand and product sales, despite facing certain challenges.
- Historical Performance Review: Over the past two years, OCUL has only beaten EPS estimates 13% of the time and revenue estimates 25% of the time, indicating volatility in financial forecasting that may affect investor confidence.
- Estimate Revision Dynamics: In the last three months, there has been one upward revision in EPS estimates with no downward revisions, while revenue estimates have seen four downward revisions, suggesting a weakening market outlook for the company’s future revenue growth, which could impact stock performance.
See More
Acuta Capital Reduces Stake in Ocular Therapeutix Significantly
- Share Reduction Details: According to an SEC filing dated May 15, Acuta Capital Partners sold 460,887 shares of Ocular Therapeutix in Q1, leaving them with 592,108 shares valued at approximately $5 million, indicating a cautious outlook on the company's future prospects.
- Asset Management Proportion: Following this sale, Ocular Therapeutix now represents only 3.5% of Acuta Capital's AUM, down from 8.7% at the end of last year, reflecting investor concerns regarding its performance.
- Company Financial Performance: As of market close on May 26, Ocular Therapeutix's stock was priced at $8.29, with a 12.7% increase over the past year, yet this lags behind the S&P 500's 30.4% and Nasdaq Composite's 41.5%, indicating poor market performance.
- Future Outlook and Risks: Despite Ocular Therapeutix conducting trials for several products, the company reported only $10.8 million in revenue for Q1 and a loss of $88.6 million, prompting investors to watch for updates during the investor day on June 17 for insights into its future developments.
See More
Acuta Capital Partners Reduces Ocular Therapeutix Holdings
- Share Reduction Details: Acuta Capital Partners reduced its holdings in Ocular Therapeutix by 460,887 shares in Q1, bringing its total to 592,108 shares valued at approximately $5 million, which now represents 3.5% of the firm's AUM.
- Market Performance Lag: Ocular Therapeutix shares gained only 12.7% over the past year, significantly trailing the S&P 500's 30.4% and the Nasdaq Composite's 41.5%, indicating investor concerns about its growth potential.
- Poor Financial Performance: The company reported only $10.8 million in revenue for Q1 while incurring a loss of $88.6 million, highlighting its vulnerability in a competitive market and necessitating cautious risk assessment by investors.
- Uncertain Future Outlook: Although Ocular Therapeutix is conducting trials for several products that could lead to significant revenue increases if successful, the uncertainty surrounding government approvals poses challenges for investment, prompting investors to watch for updates from the investor day on June 17.
See More
Saturn V Capital Management Fully Exits Ocular Therapeutix
- Full Exit from Holdings: On May 15, 2026, Saturn V Capital Management disclosed a complete exit from its 1,504,880 shares in Ocular Therapeutix, with an estimated transaction value of $14.34 million, indicating a decline in confidence in the company.
- Valuation Shift: Following the sale, Saturn V's position in Ocular fell to zero, with a quarter-end valuation shift of $18.27 million, highlighting the impact of market price fluctuations on its investment portfolio.
- Poor Financial Performance: Ocular Therapeutix reported a less than 1% revenue increase to $10.8 million in Q1, while R&D expenses surged to $66.2 million, resulting in a widened net loss of $88.6 million, reflecting significant financial pressure on the company.
- Future Outlook and Challenges: Despite positive clinical trial results, the market remains cautious about Ocular's ability to convert clinical data into commercial success, especially with a cash balance of $666.7 million, making future execution critical for its growth prospects.
See More
Saturn V Fully Exits Ocular Therapeutix Stake
- Share Sale Details: Saturn V Capital Management sold 1,504,880 shares of Ocular Therapeutix in Q1 2026, with an estimated transaction value of $14.34 million, marking a complete exit from the company, which previously represented 3.4% of the fund's AUM.
- Asset Value Decline: The fund's quarter-end position value decreased by $18.27 million due to both share sales and market price fluctuations, indicating a total divestment from Ocular and reflecting diminished confidence in the company's future prospects.
- Financial Performance Analysis: Ocular Therapeutix reported a less than 1% revenue increase to $10.8 million in Q1, while R&D expenses surged to $66.2 million, leading to a net loss of $88.6 million, highlighting financial strain amid commercialization efforts.
- Market Outlook: Despite short-term challenges, Ocular retains a cash balance of $666.7 million, projected to last until 2028, with the market eager for proof that the company can convert promising clinical data into commercial success, although analysts remain cautious about its future performance.
See More
Ocular Therapeutix Q1 2026 Earnings Call Insights
- Clinical Trial Breakthrough: Ocular Therapeutix's SOL-1 Phase III trial results indicate that AXPAXLI is the first investigational therapy to surpass an approved anti-VEGF agent in treating wet AMD, with 2/3 of patients maintaining vision for an entire year after just one injection, marking a significant advancement in the treatment landscape.
- Regulatory Pathway Planning: The company intends to submit a New Drug Application (NDA) based on SOL-1 Week 52 data and plans to leverage the 505(b)(2) pathway to shorten review timelines, a strategy that will accelerate the commercialization process for AXPAXLI.
- Strong Financial Position: As of Q1 2026, the company reported approximately $667 million in cash, expected to sustain operations into 2028, although management cautioned that this does not cover all expenses anticipated for AXPAXLI's commercialization.
- Future Outlook: Management anticipates releasing SOL-R top-line data in Q1 2027 and plans to provide detailed updates on the NDA submission strategy and commercialization plans during the Investor Day on June 17, reflecting the company's confidence in future growth.
See More
Ocular Therapeutix to Announce Q1 Earnings on May 5th
- Earnings Announcement Date: Ocular Therapeutix (OCUL) is set to announce its Q1 earnings on May 5th before market open, with a consensus EPS estimate of -$0.32, reflecting a 15.8% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Expectations: The anticipated revenue for Q1 is $12.7 million, representing an 18.7% year-over-year increase, which highlights a positive trend in market demand and product sales, despite facing certain challenges.
- Historical Performance Review: Over the past two years, OCUL has only beaten EPS estimates 13% of the time and revenue estimates 25% of the time, indicating volatility in financial forecasting that may affect investor confidence.
- Estimate Revision Dynamics: In the last three months, there has been one upward revision in EPS estimates with no downward revisions, while revenue estimates have seen four downward revisions, suggesting a weakening market outlook for the company’s future revenue growth, which could impact stock performance.
See More
